
Cardiol Therapeutics Inc. (NASDAQ:CRDL – Free Report) – Stock analysts at HC Wainwright reduced their FY2026 earnings per share estimates for Cardiol Therapeutics in a research report issued on Friday, November 13th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of ($0.25) for the year, down from their previous estimate of ($0.24). HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ FY2028 earnings at $0.26 EPS, FY2029 earnings at $0.57 EPS and FY2030 earnings at $1.18 EPS.
Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02).
Several other equities analysts also recently weighed in on CRDL. Wall Street Zen downgraded Cardiol Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiol Therapeutics in a research report on Monday, September 21st. B. Riley Financial initiated coverage on Cardiol Therapeutics in a research report on Wednesday, August 26th. They issued a “buy” rating and a $11.00 price target for the company. Finally, Canaccord Genuity Group lifted their price objective on shares of Cardiol Therapeutics from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $10.00.
Check Out Our Latest Stock Analysis on Cardiol Therapeutics
Cardiol Therapeutics Stock Down 2.0%
NASDAQ:CRDL opened at $0.98 on Tuesday. Cardiol Therapeutics has a 1 year low of $0.88 and a 1 year high of $2.34. The business has a 50 day simple moving average of $1.39 and a 200-day simple moving average of $1.30.
Institutional Trading of Cardiol Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. Concurrent Investment Advisors LLC purchased a new position in shares of Cardiol Therapeutics during the second quarter valued at approximately $27,000. Royal Bank of Canada grew its stake in shares of Cardiol Therapeutics by 62.3% during the first quarter. Royal Bank of Canada now owns 21,648 shares of the company’s stock valued at $29,000 after buying an additional 8,306 shares during the last quarter. Parallel Advisors LLC bought a new position in shares of Cardiol Therapeutics during the third quarter valued at approximately $32,000. Cibc World Market Inc. purchased a new stake in shares of Cardiol Therapeutics in the third quarter worth approximately $55,000. Finally, PVG Asset Management Corp raised its holdings in shares of Cardiol Therapeutics by 10.3% in the first quarter. PVG Asset Management Corp now owns 107,165 shares of the company’s stock worth $145,000 after buying an additional 10,000 shares during the period. Institutional investors own 12.49% of the company’s stock.
Cardiol Therapeutics Company Profile
Cardiol Therapeutics is a Canadian biotechnology company developing therapies for inflammatory heart disease and other cardiovascular conditions. Its research focuses on treatments intended to address inflammation and related damage to the heart. The company’s lead candidate, CardiolRx, is a pharmaceutical-grade cannabidiol formulation under clinical investigation for conditions including myocarditis and pericarditis. Cardiol also has CRD-38, an investigational candidate being studied for potential use in heart failure.
Read More
- Five stocks we like better than Cardiol Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
